Clinical trials: PAH
Pulmonary Arterial Hypertension (PAH)
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH).
- Trial name
- ILLUMINATE (NCT07318597)
- Testing
- REGN13335
- Where
- 33 sites in United States, Australia and 8 more
- Volunteers
- 99 people
- Sponsor
- Regeneron Pharmaceuticals
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH).
- Trial name
- ROCSTAR (NCT07175038)
- Testing
- ROC-101
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- AllRock Bio, Inc.
PAH, Pulmonary Hypertension
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
- Trial name
- NCT03683186
- Testing
- Ralinepag
- Where
- 190 sites in United States, Argentina and 31 more
- Volunteers
- 1,000 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension (PAH)
A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag
This study will look at safety and tolerability of LIQ861 (treprostinil) inhalation powder in adults with pulmonary arterial hypertension (PAH, WHO Group 1) who switch from selexipag, a medicine taken by mouth, to treprostinil, a…
- Trial name
- NCT07759804
- Testing
- LIQ861 (treprostinil) inhalation powder
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Liquidia Technologies, Inc.
Pulmonary Arterial Hypertension (PAH)
TREPROSTINIL in Pulmonary Hypertension: Evidence and Clinical Trends
TRESPECT is an international, multicenter, observational registry designed to describe the real-world use, effectiveness, and tolerability of parenteral treprostinil in adults with newly diagnosed pulmonary arterial hypertension…
- Trial name
- NCT07736846
- Testing
- treprostinil
- Volunteers
- 300 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Arterial Hypertension (PAH)
Bioequivalence Study to Compare Selexipag 400 Microgram Film Coated Tablets Versus Uptravi® (Selexipag) 400 Microgram Film Coated Tablets
An open label, randomized, Three treatment, Three sequence, Three period, Three way crossover, single dose oral bioequivalence study to compare Selexipag 400 microgram film coated tablets versus Uptravi® (selexipag) 400 microgram…
- Trial name
- NCT07694128
- Testing
- Selexipag Film Coated Tablets (T1), Selexipag Film Coated Tablets (T2), Uptravi® (selexipag) film coated tablets
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
PAH, Pulmonary Hypertension
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health…
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
- Trial name
- NCT03626688
- Testing
- Ralinepag
- Where
- 209 sites in United States, Argentina and 31 more
- Volunteers
- 687 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension (PAH)
Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)
This is a multicenter, open-label extension (OLE), single-arm study designed to assess the long-term safety and tolerability of oral IKT-001 administered once daily.
- Trial name
- NCT07632898
- Testing
- IKT-001
- Volunteers
- 484 people
- Sponsor
- Inhibikase Therapeutics
Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH)
A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
This study evaluates the effects of VI-0106 (an extended-release formulation of tacrolimus) in participants with pulmonary arterial hypertension (PAH) who continue to have functional limitations despite being on optimized…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension PAH
- Trial name
- TRANSCEND (NCT07612657)
- Testing
- VI-0106
- Volunteers
- 300 people
- Sponsor
- VIVUS LLC
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Combination therapy in pulmonary arterial hypertension (PAH) has been the subject of active investigation for more than a decade, with the benefit of targeting different pathways known to be involved in the pathogenesis of the…
- Trial name
- A DUE (NCT03904693)
- Testing
- FDC macitentan/tadalafil, Macitentan 10 mg, Tadalafil 40 mg
- Where
- 148 sites in United States, Australia and 17 more
- Volunteers
- 187 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)
This is a randomized, double-blind, multi-center, placebo-controlled dose-ranging clinical trial of two IkT-001Pro doses in patients with PAH designed to assess safety, tolerability and efficacy.
- Trial name
- NCT06643143
- Testing
- IkT-001Pro
- Sponsor
- Inhibikase Therapeutics
Pulmonary Arterial Hypertension (PAH)
A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults
A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults
- Trial name
- NCT06493461
- Testing
- HS135
- Where
- 2 sites in Canada, Germany
- Volunteers
- 5 people
- Sponsor
- 35Pharma Inc
Pulmonary Arterial Hypertension (PAH)
Bioequivalence Study to Compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) Versus Uptravi® 400mcg Film Coated Tablets (400 mcg Selexipag)
Randomized, single oral dose, two-period, two-treatment, two-sequence open-label, crossover, bioequivalence study to compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) versus Uptravi® 400mcg Film Coated Tablets (400…
- Trial name
- NCT06932198
- Testing
- Selexipag Film Coated Tablets, Uptravi® Film Coated Tablets
- Where
- Jordan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
PAH
Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
This was a multi-center, open-label, safety, tolerability and pharmacokinetic study of oral treprostinil in pediatric subjects with stable PAH aged 7 to 17 years who were (1) transitioning from parenteral Remodulin therapy; (2)…
- Trial name
- NCT02276872
- Testing
- oral treprostinil
- Where
- 9 sites in United States
- Volunteers
- 32 people
- Sponsor
- United Therapeutics
PAH
Bioequivalence Study of Macitentan and Tadalafil Film-coated Tablets 10 Mg/40 Mg and 'PrOpsynvi®' Macitentan and Tadalafil Film-coated Tablets 10 Mg/40 Mg
Single dose oral bioequivalence study of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg and 'PrOpsynvi®' Macitentan and Tadalafil film-coated tablets 10 mg/40 mg in healthy adult male subjects under fed conditions.
- Trial name
- NCT06553937
- Testing
- Macitentan and Tadalafil, PrOpsynvi® Film-Coated Tablets
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
PAH
Macitentan and Tadalafil Film-coated Tablets 10 mg/40 mg and 'PrOpsynvi®' Macitentan and Tadalafil Film-coated Tablets 10 mg/40 mg
Single dose oral bioequivalence study of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg and 'PrOpsynvi®' Macitentan and Tadalafil film-coated tablets 10 mg/40 mg in healthy adult male subjects under fasting conditions.
- Trial name
- NCT06553924
- Testing
- Macitentan and Tadalafil film-coated tablets, PrOpsynvi® macitentan and tadalafil film-coated tablets
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Phenylketonurias, PAH Deficiency
Safety and Efficacy of HMI-103 in Participants With Classical PKU Due to PAH Deficiency
This is an open-label, sequential ascending dose-escalation, Phase 1 study to evaluate the safety and efficacy of a single intravenous (I.V.) administration of HMI-103, a gene editing development candidate, in adult participants…
- Conditions
- Phenylketonurias, PAH Deficiency, Phenylketonuria
- Trial name
- NCT05222178
- Testing
- HMI-103
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Homology Medicines, Inc
Phenylketonurias, PAH Deficiency
Gene Therapy Clinical Study in Adult PKU
This is a Phase 1/2, open-label, randomized, concurrently-controlled, dose escalation study to evaluate the safety and efficacy of HMI-102 in adult PKU subjects with PAH deficiency.
- Trial name
- pheNIX (NCT03952156)
- Testing
- HMI-102
- Where
- 13 sites in United States
- Volunteers
- 10 people
- Sponsor
- Homology Medicines, Inc
Pulmonary Arterial Hypertension (PAH)
a Non-interventional Study of Sildenafil in the Treatment of Pulmonary Arterial Hypertension (PAH) in Adults From China
This observational study will involve analysis of data collected by the National Rare Disease Registry or medical records .The study will describe outcomes only in PAH(Pulmonary arterial hypertension) patients treated with…
- Trial name
- NCT05546125
- Testing
- as per Physician's prescription
- Where
- 7 sites in China
- Volunteers
- 100 people
- Sponsor
- Pfizer Pharmaceuticals Ltd.
Phenylketonuria, PAH Deficiency
Long-Term Follow Up Study of Subjects Previously Administered HMI 102
An Open-Label, Long-Term Follow Up Study of Safety and Efficacy in PKU Subjects with PAH Deficiency Previously Administered HMI 102
- Trial name
- NCT04348708
- Testing
- HMI-102
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Homology Medicines, Inc